MYD88 and coronary artery disorder: It had been reported that attenuating TLR-4 signaling was a potential effective therapy for coronary artery disease [29], and the inhibition of the ROS generation, expression of TLR-4 mRNA, MyD88 mRNA and TRAF-6 mRNA in LPS-stimulated THP-1 cells with CSP-1 treatment is strong evidence for its potential immunomodulatory activities.